Engineered T-Cells Market By Product Type (CAR T-Cells, TCR T-Cells), By Application (Oncology, Infectious Diseases, Autoimmune Disorders), By End User (Hospitals, Research Institutes, Biotechnology & Pharmaceutical Companies), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Engineered T-Cells Market was valued at USD 3.5 billion in 2023 and will surpass USD 9.2 billion by 2030; growing at a CAGR of 15.1% during 2024 - 2030.

The engineered T-cells market is experiencing rapid growth, driven by advancements in immunotherapy and the increasing prevalence of chronic diseases such as cancer and autoimmune disorders. Engineered T-cells, particularly CAR T-cells and TCR T-cells, have shown significant promise in treating a variety of conditions by harnessing the power of the immune system to target and eliminate disease-causing cells. This technology offers the potential for highly targeted treatments with reduced side effects, making it a transformative approach, particularly in oncology. The increasing investment in research and development in this field is accelerating the clinical adoption of engineered T-cell therapies, positioning the market for substantial growth.

The demand for engineered T-cells is expected to rise as more healthcare institutions adopt these advanced therapies to treat difficult-to-treat conditions. As regulatory agencies like the FDA approve more CAR T-cell and TCR T-cell therapies, the market’s potential continues to expand. With the increasing recognition of the benefits of T-cell-based therapies in cancer treatment, the market is becoming a focal point for pharmaceutical companies and research institutions worldwide, driving continued innovation and market evolution.

CAR T-Cells are the Largest Product Type in Engineered T-Cells

CAR T-cells (Chimeric Antigen Receptor T-cells) are the largest product type in the engineered T-cells market, primarily due to their breakthrough success in treating hematologic cancers such as leukemia and lymphoma. CAR T-cell therapy involves modifying a patient’s T-cells to express a receptor specific to cancer cells, enabling the immune system to target and kill those cells. The success of CAR T-cell therapies, such as Kymriah and Yescarta, in treating previously untreatable cancers has significantly boosted the market for these products.

The widespread adoption of CAR T-cells, along with the growing number of ongoing clinical trials exploring their use in other cancers, contributes to their dominance in the market. The robust pipeline of CAR T-cell therapies under development further supports the expansion of this segment, as more cancer types are targeted. The availability of CAR T-cells in both commercial and investigational settings continues to make them a cornerstone of engineered T-cell therapy, ensuring their sustained growth and market leadership.

Oncology is the Largest Application for Engineered T-Cells

Oncology is the largest application for engineered T-cells, particularly CAR T-cells, owing to their groundbreaking success in the treatment of blood cancers like leukemia, lymphoma, and myeloma. The development of engineered T-cell therapies has revolutionized cancer treatment by providing a more targeted approach compared to traditional treatments like chemotherapy and radiation. These therapies have shown the ability to induce long-lasting remissions in patients with refractory cancers, offering hope for those who have exhausted all other treatment options.

The oncology application is expected to remain the largest segment in the engineered T-cells market as clinical trials expand into solid tumors and other types of cancer. The ability of engineered T-cells to specifically target and destroy cancerous cells while sparing healthy tissues offers significant advantages, further driving their adoption in oncology. As research progresses, the continued success of CAR T-cell therapies in oncology will likely solidify this segment as the dominant force in the market.

Hospitals are the Largest End-User of Engineered T-Cells

Hospitals are the largest end-user of engineered T-cells, especially as CAR T-cell therapies become more widely adopted for treating cancer patients. Hospitals are central to the administration of these therapies, with specialized teams overseeing the patient’s T-cell modification, infusion, and subsequent monitoring. The demand for engineered T-cells in hospitals is fueled by the increasing number of cancer patients seeking innovative therapies, as well as the approval of new CAR T-cell and TCR T-cell treatments by regulatory bodies.

Furthermore, hospitals are critical in facilitating the complex manufacturing and logistical processes involved in CAR T-cell therapy, which includes the collection of a patient’s T-cells, their modification in a lab, and their reintroduction into the patient’s body. The growing acceptance of engineered T-cell therapies in clinical settings is expected to continue driving demand within hospitals, reinforcing their position as the largest end-user of these products.

North America is the Largest Region for Engineered T-Cells

North America holds the largest market share for engineered T-cells, driven by the advanced healthcare infrastructure, high levels of research funding, and early adoption of innovative therapies in the region. The United States, in particular, has been at the forefront of engineered T-cell therapy development, with several approved CAR T-cell products already in use for cancer treatment. The strong presence of major biotechnology and pharmaceutical companies in North America has also contributed to the growth of the engineered T-cells market.

Regulatory approval from agencies such as the U.S. Food and Drug Administration (FDA) has paved the way for the commercialization of CAR T-cell therapies, ensuring that patients in North America have access to cutting-edge treatments. Furthermore, the growing investment in research and development of engineered T-cell therapies is expected to drive continued growth in this region, making North America the dominant market for these therapies.

Competitive Landscape and Leading Companies

The engineered T-cells market is highly competitive, with leading companies like Novartis, Gilead Sciences, Bristol Myers Squibb, and Kite Pharma playing a prominent role in the development and commercialization of CAR T-cell therapies. These companies are investing heavily in expanding their product portfolios, focusing on both novel indications and the development of next-generation engineered T-cells. Partnerships and collaborations with research institutions and biotechnology firms are also common as companies seek to enhance their capabilities and bring innovative therapies to market faster.

The competitive landscape is expected to become more dynamic as new players enter the market and as clinical trials explore new applications for engineered T-cells, particularly in oncology and infectious diseases. Ongoing advancements in genetic engineering and immune cell modification technologies will continue to shape the competitive environment, with companies striving to stay ahead in the race to offer the most effective and scalable engineered T-cell therapies.

Recent Developments:

• In October 2024, Gilead Sciences’ Kite Pharma received FDA approval for a new CAR T-cell therapy targeting relapsed lymphoma.
• In September 2024, Novartis announced advancements in allogeneic T-cell therapies, aiming for off-the-shelf solutions.
• In August 2024, Bristol Myers Squibb expanded its pipeline with the acquisition of a TCR therapy startup.
• In July 2024, Adaptimmune Therapeutics reported positive results in a Phase II trial for engineered T-cells targeting melanoma.
• In June 2024, Bluebird Bio launched a new manufacturing facility to scale its CAR T-cell therapy production.

List of Leading Companies:

• Novartis AG
• Gilead Sciences, Inc. (Kite Pharma)
• Bristol Myers Squibb
• Johnson & Johnson (Janssen Pharmaceuticals)
• Celgene Corporation
• Bluebird Bio, Inc.
• Allogene Therapeutics, Inc.
• Cellectis S.A.
• Adaptimmune Therapeutics PLC
• CRISPR Therapeutics AG
• Fate Therapeutics, Inc.
• Precision BioSciences, Inc.
• Atara Biotherapeutics, Inc.
• Autolus Therapeutics PLC
• Poseida Therapeutics, Inc.

Report Scope: